IL17A and COVID-19: Data on IL-17A inhibitor, such as secukinumab, in COVID-19 is limited but a recent study showed that the secukinumab-baricitinib combination therapy compared to baricitinib single therapy in COVID-19 showed lower rate of ICU and MV requirement (23.53%/52.94%, p = .02; 11.76%/29.41%, p = .011) with decreased 30-day mortality rate (5.88%/17.65%, p = .033) [17].